These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30601402)

  • 1. Long-term Efficacy of Single-agent Vemurafenib for Pleomorphic Xanthoastrocytoma.
    Finch EA; Elton SW; Huang BY; Trembath DG; Blatt J
    J Pediatr Hematol Oncol; 2020 Mar; 42(2):152-155. PubMed ID: 30601402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib.
    van Tilburg CM; Selt F; Sahm F; Bächli H; Pfister SM; Witt O; Milde T
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29230924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma.
    Lukas RV; Merrell RT
    CNS Oncol; 2018 Apr; 7(2):CNS10. PubMed ID: 29708404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.
    Lee EQ; Ruland S; LeBoeuf NR; Wen PY; Santagata S
    J Clin Oncol; 2016 Apr; 34(10):e87-9. PubMed ID: 25092772
    [No Abstract]   [Full Text] [Related]  

  • 5. Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.
    Brown NF; Carter T; Mulholland P
    CNS Oncol; 2017 Jan; 6(1):5-9. PubMed ID: 27781490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
    Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
    J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete Remission of an Extracranially Disseminated Anaplastic Pleomorphic Xanthoastrocytoma With Everolimus: A Case Report and Literature Review.
    Saraf AJ; Elhawary G; Finlay JL; Scott S; Olshefski R; Halverson M; Boue DR; AbdelBaki MS
    Pediatr Neurol; 2018 Nov; 88():65-70. PubMed ID: 30322731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
    Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
    Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic BRAF c.1799T>A p.V600E Mosaicism syndrome characterized by a linear syringocystadenoma papilliferum, anaplastic astrocytoma, and ocular abnormalities.
    Watanabe Y; Shido K; Niihori T; Niizuma H; Katata Y; Iizuka C; Oba D; Moriya K; Saito-Nanjo Y; Onuma M; Rikiishi T; Sasahara Y; Watanabe M; Aiba S; Saito R; Sonoda Y; Tominaga T; Aoki Y; Kure S
    Am J Med Genet A; 2016 Jan; 170A(1):189-94. PubMed ID: 26360803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to BRAF/MEK Inhibition After Progression With BRAF Inhibition in a Patient With Anaplastic Pleomorphic Xanthoastrocytoma.
    Hussain F; Horbinski CM; Chmura SJ; Yamini B; Lukas RV
    Neurologist; 2018 Sep; 23(5):163-166. PubMed ID: 30169370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF Inhibition in
    Kaley T; Touat M; Subbiah V; Hollebecque A; Rodon J; Lockhart AC; Keedy V; Bielle F; Hofheinz RD; Joly F; Blay JY; Chau I; Puzanov I; Raje NS; Wolf J; DeAngelis LM; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM
    J Clin Oncol; 2018 Dec; 36(35):3477-3484. PubMed ID: 30351999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilomyxoid astrocytoma treated successfully with vemurafenib.
    Skrypek M; Foreman N; Guillaume D; Moertel C
    Pediatr Blood Cancer; 2014 Nov; 61(11):2099-100. PubMed ID: 24821190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary Meningeal Pleomorphic Xanthoastrocytoma With Anaplastic Features: A Report of 2 Cases, One With BRAF(V600E) Mutation and Clinical Response to the BRAF Inhibitor Dabrafenib.
    Usubalieva A; Pierson CR; Kavran CA; Huntoon K; Kryvenko ON; Mayer TG; Zhao W; Rock J; Ammirati M; Puduvalli VK; Lehman NL
    J Neuropathol Exp Neurol; 2015 Oct; 74(10):960-9. PubMed ID: 26352988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
    Robinson SD; O'Shaughnessy JA; Cowey CL; Konduri K
    Lung Cancer; 2014 Aug; 85(2):326-30. PubMed ID: 24888229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
    Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
    Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined pleomorphic xanthoastrocytoma-ganglioglioma with BRAF V600E mutation: case report.
    Cicuendez M; Martinez-Saez E; Martinez-Ricarte F; Asanza EC; Sahuquillo J
    J Neurosurg Pediatr; 2016 Jul; 18(1):53-7. PubMed ID: 27015517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant progression in pleomorphic xanthoastrocytoma: personal experience and review of the literature.
    Marton E; Feletti A; Orvieto E; Longatti P
    J Neurol Sci; 2007 Jan; 252(2):144-53. PubMed ID: 17189643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaplastic pleomorphic xanthoastrocytoma with leptomeningeal dissemination responsive to BRAF inhibition and bevacizumab.
    Thomas AA; Tucker SM; Nelson CJ; Nickerson JP; Durham SR; Homans AC
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27465. PubMed ID: 30255633
    [No Abstract]   [Full Text] [Related]  

  • 19. An open-label, multicentre safety study of vemurafenib in patients with BRAF
    Larkin J; Brown MP; Arance AM; Hauschild A; Queirolo P; Vecchio MD; Ascierto PA; Krajsová I; Schachter J; Neyns B; Garbe C; Sileni VC; Mandalà M; Gogas H; Espinosa E; Hospers G; Lorigan P; Nyakas M; Guminski A; Liszkay G; Rutkowski P; Miller W; Donica M; Makrutzki M; Blank C
    Eur J Cancer; 2019 Jan; 107():175-185. PubMed ID: 30580112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma.
    Wang J; Liu Z; Cui Y; Liu Y; Fang J; Xu L; He Y; Du J; Su Y; Zou W; Xu Z; Li G
    J Neurooncol; 2019 Aug; 144(1):137-146. PubMed ID: 31214915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.